Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48


SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial.

Ikeno F, Brooks MM, Nakagawa K, Kim MK, Kaneda H, Mitsutake Y, Vlachos HA, Schwartz L, Frye RL, Kelsey SF, Waseda K, Hlatky MA; BARI-2D Study Group.

J Am Coll Cardiol. 2017 Jan 31;69(4):395-403. doi: 10.1016/j.jacc.2016.10.067.


Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease.

Zonszein J, Groop PH.

Diabetes Ther. 2016 Dec;7(4):621-639. Epub 2016 Oct 31. Review.


Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes.

Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL; BARI 2D Study Group.

N Engl J Med. 2015 Aug 13;373(7):610-20. doi: 10.1056/NEJMoa1415921.


Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D.

Zonszein J, Lombardero M, Ismail-Beigi F, Palumbo P, Foucher S, Groenewoud Y, Cushing G, Wajchenberg B, Genuth S; Bari 2D Study Group.

J Diabetes Res. 2015;2015:129891. doi: 10.1155/2015/129891. Epub 2015 May 27.


Understanding hypoglycemia in hospitalized patients.

Hulkower RD, Pollack RM, Zonszein J.

Diabetes Manag (Lond). 2014 Mar;4(2):165-176.


Is there a paradox in obesity?

Goyal A, Nimmakayala KR, Zonszein J.

Cardiol Rev. 2014 Jul-Aug;22(4):163-70. doi: 10.1097/CRD.0000000000000004. Review.


The clinical impact of inpatient hypoglycemia.

Brutsaert E, Carey M, Zonszein J.

J Diabetes Complications. 2014 Jul-Aug;28(4):565-72. doi: 10.1016/j.jdiacomp.2014.03.002. Epub 2014 Mar 10. Review.


Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program.

Dabelea D, Ma Y, Knowler WC, Marcovina S, Saudek CD, Arakaki R, White NH, Kahn SE, Orchard TJ, Goldberg R, Palmer J, Hamman RF; Diabetes Prevention Program Research Group.

Diabet Med. 2014 Sep;31(9):1064-8. doi: 10.1111/dme.12437. Epub 2014 Apr 9.


Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program.

Walford GA, Ma Y, Christophi CA, Goldberg RB, Jarolim P, Horton E, Mather KJ, Barrett-Connor E, Davis J, Florez JC, Wang TJ; Diabetes Prevention Program Research Group.

Diabetologia. 2014 May;57(5):935-9. doi: 10.1007/s00125-014-3183-2. Epub 2014 Feb 20.


Short and long-term lifestyle coaching approaches used to address diverse participant barriers to weight loss and physical activity adherence.

Venditti EM, Wylie-Rosett J, Delahanty LM, Mele L, Hoskin MA, Edelstein SL; Diabetes Prevention Program Research Group.

Int J Behav Nutr Phys Act. 2014 Feb 12;11:16. doi: 10.1186/1479-5868-11-16.


Common variation at PPARGC1A/B and change in body composition and metabolic traits following preventive interventions: the Diabetes Prevention Program.

Franks PW, Christophi CA, Jablonski KA, Billings LK, Delahanty LM, Horton ES, Knowler WC, Florez JC; Diabetes Prevention Program Research Group.

Diabetologia. 2014 Mar;57(3):485-90. doi: 10.1007/s00125-013-3133-4. Epub 2013 Dec 7.


Population management of diabetes in a high-need urban community in the Bronx: the experience of Montefiore Medical Center.

Farrell P, Barnaby S, Galarza T, Simonson JK, Zonszein J, Meara A, Chung H, Figueira R, Felleman S.

Diabetes Educ. 2013 Jul-Aug;39(4):515-22. doi: 10.1177/0145721713487259. Epub 2013 May 14.


Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysis.

Ismail-Beigi F, Lombardero MS, Escobedo J, Genuth S, Green J, Massaro E, Mooradian AD, Ovalle F, Whitehouse F, Zonszein J; BARI 2D Study Group.

J Diabetes Complications. 2014 Jan-Feb;28(1):101-9. doi: 10.1016/j.jdiacomp.2013.01.006. Epub 2013 Mar 7.


Confirming glycemic status in the Diabetes Prevention Program: implications for diagnosing diabetes in high risk adults.

Christophi CA, Resnick HE, Ratner RE, Temprosa M, Fowler S, Knowler WC, Shamoon H, Barrett-Connor E, Kahn SE; Diabetes Prevention Program Research Group.

J Diabetes Complications. 2013 Mar-Apr;27(2):150-7. doi: 10.1016/j.jdiacomp.2012.09.012. Epub 2012 Nov 7.


Impact of hypoglycemia in hospitalized patients.

Carey M, Boucai L, Zonszein J.

Curr Diab Rep. 2013 Feb;13(1):107-13. doi: 10.1007/s11892-012-0336-x. Review.


Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program.

Florez JC, Jablonski KA, McAteer JB, Franks PW, Mason CC, Mather K, Horton E, Goldberg R, Dabelea D, Kahn SE, Arakaki RF, Shuldiner AR, Knowler WC; Diabetes Prevention Program Research Group.

PLoS One. 2012;7(9):e44424. doi: 10.1371/journal.pone.0044424. Epub 2012 Sep 11.


Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: the Diabetes Prevention Program.

Pollin TI, Isakova T, Jablonski KA, de Bakker PI, Taylor A, McAteer J, Pan Q, Horton ES, Delahanty LM, Altshuler D, Shuldiner AR, Goldberg RB, Florez JC, Franks PW; Diabetes Prevention Program Research Group.

PLoS Genet. 2012;8(8):e1002895. Epub 2012 Aug 30.


The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program.

Florez JC, Jablonski KA, Taylor A, Mather K, Horton E, White NH, Barrett-Connor E, Knowler WC, Shuldiner AR, Pollin TI; Diabetes Prevention Program Research Group.

Diabetes Care. 2012 Sep;35(9):1864-7. Epub 2012 Jun 29.


Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.

DeVries JH, Bain SC, Rodbard HW, Seufert J, D'Alessio D, Thomsen AB, Zychma M, Rosenstock J; Liraglutide-Detemir Study Group.

Diabetes Care. 2012 Jul;35(7):1446-54. doi: 10.2337/dc11-1928. Epub 2012 May 14.


Patient guide to managing hyperglycemia (high blood sugar) in the hospital.

Korytkowski M, McDonnell ME, Umpierrez GE, Zonszein J.

J Clin Endocrinol Metab. 2012 Jan;97(1):27A-8A. No abstract available.


Supplemental Content

Loading ...
Support Center